Cargando…
Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process
A drug–drug and drug–excipient interactions and compatibilities study was conducted for two fixed-dose combination (FDC) products containing olmesartan medoxomil (OLM)/hydrochlorothiazide (HCT) 20/12.5 mg and OLM/HCT 40/12.5 mg during their development including storage. The study consisted of the e...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875139/ https://www.ncbi.nlm.nih.gov/pubmed/35214156 http://dx.doi.org/10.3390/pharmaceutics14020424 |
_version_ | 1784657845778644992 |
---|---|
author | Murillo-Fernández, Mac Arturo Montero-Zeledón, Ernesto Abdala-Saiz, Ariadna Vega-Baudrit, José Roberto Araya-Sibaja, Andrea Mariela |
author_facet | Murillo-Fernández, Mac Arturo Montero-Zeledón, Ernesto Abdala-Saiz, Ariadna Vega-Baudrit, José Roberto Araya-Sibaja, Andrea Mariela |
author_sort | Murillo-Fernández, Mac Arturo |
collection | PubMed |
description | A drug–drug and drug–excipient interactions and compatibilities study was conducted for two fixed-dose combination (FDC) products containing olmesartan medoxomil (OLM)/hydrochlorothiazide (HCT) 20/12.5 mg and OLM/HCT 40/12.5 mg during their development including storage. The study consisted of the evaluation of samples retrieved during all stages of a real manufacturing process. Powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), thermogravimetry (TGA), Fourier transform infrared spectroscopy (FT-IR), and contact angle techniques were applied to the samples to determine interactions and incompatibilities. Dissolution tests and long-term stability studies were conducted to evaluate dosage form performance. Results showed weak solid–state interactions able to obtain a eutectic mixture of OLM and HCT while microcrystalline cellulose (MC) impacted the thermal stability of both drugs. Reliable dissolution and long-term stability tests confirmed that the interactions observed were not considered incompatibilities because they were not influenced by the performance of the final products. |
format | Online Article Text |
id | pubmed-8875139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88751392022-02-26 Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process Murillo-Fernández, Mac Arturo Montero-Zeledón, Ernesto Abdala-Saiz, Ariadna Vega-Baudrit, José Roberto Araya-Sibaja, Andrea Mariela Pharmaceutics Article A drug–drug and drug–excipient interactions and compatibilities study was conducted for two fixed-dose combination (FDC) products containing olmesartan medoxomil (OLM)/hydrochlorothiazide (HCT) 20/12.5 mg and OLM/HCT 40/12.5 mg during their development including storage. The study consisted of the evaluation of samples retrieved during all stages of a real manufacturing process. Powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), thermogravimetry (TGA), Fourier transform infrared spectroscopy (FT-IR), and contact angle techniques were applied to the samples to determine interactions and incompatibilities. Dissolution tests and long-term stability studies were conducted to evaluate dosage form performance. Results showed weak solid–state interactions able to obtain a eutectic mixture of OLM and HCT while microcrystalline cellulose (MC) impacted the thermal stability of both drugs. Reliable dissolution and long-term stability tests confirmed that the interactions observed were not considered incompatibilities because they were not influenced by the performance of the final products. MDPI 2022-02-16 /pmc/articles/PMC8875139/ /pubmed/35214156 http://dx.doi.org/10.3390/pharmaceutics14020424 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Murillo-Fernández, Mac Arturo Montero-Zeledón, Ernesto Abdala-Saiz, Ariadna Vega-Baudrit, José Roberto Araya-Sibaja, Andrea Mariela Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process |
title | Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process |
title_full | Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process |
title_fullStr | Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process |
title_full_unstemmed | Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process |
title_short | Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process |
title_sort | interaction and compatibility studies in the development of olmesartan medoxomil and hydrochlorothiazide formulations under a real manufacturing process |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875139/ https://www.ncbi.nlm.nih.gov/pubmed/35214156 http://dx.doi.org/10.3390/pharmaceutics14020424 |
work_keys_str_mv | AT murillofernandezmacarturo interactionandcompatibilitystudiesinthedevelopmentofolmesartanmedoxomilandhydrochlorothiazideformulationsunderarealmanufacturingprocess AT monterozeledonernesto interactionandcompatibilitystudiesinthedevelopmentofolmesartanmedoxomilandhydrochlorothiazideformulationsunderarealmanufacturingprocess AT abdalasaizariadna interactionandcompatibilitystudiesinthedevelopmentofolmesartanmedoxomilandhydrochlorothiazideformulationsunderarealmanufacturingprocess AT vegabaudritjoseroberto interactionandcompatibilitystudiesinthedevelopmentofolmesartanmedoxomilandhydrochlorothiazideformulationsunderarealmanufacturingprocess AT arayasibajaandreamariela interactionandcompatibilitystudiesinthedevelopmentofolmesartanmedoxomilandhydrochlorothiazideformulationsunderarealmanufacturingprocess |